

Prof. Dr. Markus W. Büchler

Director Department of General Surgery, Heidelberg
Speaker Tumor Center HD/MA



22.7.1955

Department of Surgery
Im Neuenheimer Feld 110
69120 Heidelberg

06221-56 6200 (phone)

06221-56 5450 (fax)

markus.buechler@med.uni-heidelberg.de

SCIENTIFIC VITA

- 1980 Thesis: "Structural analysis of the Meckel's Diverticulum with special consideration to endocrine cells" - University of Heidelberg
- 1987 Surgical specialist fellowship - Department of Surgery, University of Ulm
- 1987 Consultant - Department of Surgery, University of Ulm
- 1987 Postdoctoral lecture qualification (Ph. D. Equivalent) - Department of Surgery, University of Ulm
- 1991 Vice Chairman, Department of Surgery, University of Ulm
- 1991 University Professor lecturer (C2), Department of Surgery, University of Ulm
- 1993-2001 Professor of Surgery and Chairman, Department of Visceral and Transplantation Surgery, University of Bern/Switzerland
- since 2001 Professor of Surgery and Chairman, Department of General Surgery Heidelberg

AWARDS

Ludwig-Rehn-Award der Vereinigung Mittelrheinischer Chirurgen (1987); Research Award from the Society of Computed Body Tomography (1991); Award from the European Association for Gastroenterology and Endoscopy (1993); Research Prize from the Swiss Association of Surgery (1995); Prize for Surgery, Swiss Association of Surgery (1996); Fritz-Linder-Forum Preis der Deutschen Gesellschaft für Chirurgie (1999); Central Patient Management in Surgery, Healthcare Quality Promotion Prize (Recognition Prize) Baden-Württemberg (2002); Ethicon Promotion Prize "Conception and Evaluation of a Training Module for Robotic Assisted Laparoscopic Surgery" SALTC-AMIC-CAMIC (2003); Max Siurala Award, Finnish Society of Gastroenterology (2005); Gimbernat Prize, Catalan Society of Surgery (2005); Hippocrates Award of Hellenic Society of Internal Medicine (2006).

FIELDS OF INTEREST

Pancreatic cancer; molecular pathogenesis; role of growth factors and receptors, high throughput analysis; transcriptomics; proteomics; mechanisms of chemoresistance; radiotherapy and apoptosis; mechanisms of invasion and metastasis; randomized controlled clinical studies.

SELECTED PUBLICATIONS (SINCE 2000)

Schmidt J, Ryschich E, Sievers E, Schmidt-Wolf IG, Buchler MW, Marten A (2006). Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo. **Cancer** 106, 759-764

Schmitz-Winnenthal FH, Volk C, Z'graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Buchler MW, Beckhove P (2005). High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. **Cancer Res** 65, 10079-10087

Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, Meuer S, Buchler MW, Friess H (2005). Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. **Clin Cancer Res** 11, 3790-3798

Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005). Colorectal cancer. **Lancet** 365, 153-165

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. **N Engl J Med** 350, 1200-1210

Arnold NB, Ketterer K, Kleeff J, Friess H, Buchler MW, Korc M (2004). Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. **Cancer Res** 64, 3599-3606

Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, Korc M, Friess H (2003). Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. **Gastroenterology** 124, 1830-1845

Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003). Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. **Lab Invest** 83, 731-742

Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001). Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. **Lancet** 358, 1576-1585

Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodyavsky I, Zimmermann A, Buchler MW (2001). Heparanase expression in primary and metastatic pancreatic cancer. **Cancer Res** 61, 4655-4659